Opportunity Information: Apply for PAR 17 201
The Blueprint Neurotherapeutics Network (BPN) U44 opportunity is an NIH cooperative agreement designed to help small businesses push promising small molecule programs for nervous system disorders further down the drug development pipeline, with a clear emphasis on getting viable candidates into clinical testing. The program is structured to support real translational work rather than early exploratory science, meaning applicants are expected to bring forward projects with a reasonable path toward a drug candidate and to execute a milestone-driven plan that advances compounds toward an Investigational New Drug (IND) submission and first-in-human studies.
A central feature of the BPN model is the division of labor between the awardee and NIH-supported resources. The small business awardee remains responsible for the disease- and target-specific parts of the project, including creating or running specialized assays, employing proprietary disease models, using target validation tools, and generating the biology and pharmacology data that depends on the applicant's unique expertise. Importantly, the grant covers the work performed in the awardee's own labs for these project-specific activities. At the same time, the awardee gains access to a broader development infrastructure through collaboration with NIH-funded consultants and optional use of NIH contract research organizations (CROs). These CROs can supply capabilities that many small companies lack in-house, such as medicinal chemistry support, pharmacokinetics and ADME studies, safety and toxicology testing, formulation development, scale-up and chemical synthesis, Good Manufacturing Practices (GMP) manufacturing, and Phase I clinical testing. In practice, this setup is meant to reduce bottlenecks that often stall small molecule programs, especially when they move from academic-style discovery into regulated preclinical and clinical workflows.
Projects can enter the program at two different points depending on their maturity. At the Discovery stage, the goal is to take promising "hit" compounds and optimize them through medicinal chemistry and iterative testing, typically focusing on potency, selectivity, physicochemical properties, metabolic stability, brain penetration when relevant, and early safety liabilities. If a Discovery-stage project meets agreed milestones, it can transition forward into Development activities under the same overall program pathway. At the Development stage, the expectation is that the applicant already has a credible development candidate (or is close) and needs support to complete IND-enabling work. That usually includes formal toxicology studies performed under appropriate standards, required pharmacology packages, formulation and manufacturing plans suitable for human dosing, and then execution of Phase I clinical testing to establish initial safety, tolerability, and pharmacokinetics in people. The throughline is practical readiness for clinical entry rather than open-ended research.
Because this is a cooperative agreement (U44), NIH involvement is typically more hands-on than a standard grant. While the applicant drives the scientific strategy and execution of their specialized work, the program is built around coordinated project management, the use of external experts, and milestone-based decision points. This kind of structure is meant to keep projects moving, prioritize resources toward candidates that continue to meet performance and safety criteria, and provide the kind of development discipline that is often necessary to reach the clinic.
The opportunity is specifically aimed at small businesses as eligible applicants. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply under the stated terms. However, foreign components may be allowed in some cases as defined by the NIH Grants Policy Statement, so applicants with any international collaborations would need to pay close attention to the eligibility and component rules in the full funding opportunity announcement.
The intellectual property arrangement is another major incentive. Awardee institutions retain their own IP rights and, notably, receive assignment of IP rights from BPN contractors for drug candidates developed within the program. That means the small business is positioned to control downstream patent prosecution and licensing negotiations for candidates advanced through BPN-supported contractor work, which can be critical for attracting partners or investors later. This feature is meant to ensure that participating companies do not lose control of their assets simply because key development steps were executed with NIH-associated contractors.
Administrative details in the source information identify the funding opportunity as PAR 17-201, offered by the National Institutes of Health, categorized as discretionary funding, and using the U44 cooperative agreement mechanism. The activity category is listed broadly under education, health, income security, and social services, and the program aligns with multiple CFDA numbers (93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.865, 93.866, 93.867), reflecting the multi-institute nature of NIH neuroscience and translational therapeutic development efforts. The original closing date shown is 2017-12-21, and the record creation date is 2017-03-09, indicating this specific listing refers to that historical solicitation cycle.Apply for PAR 17 201
- The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.865, 93.866, 93.867.
- This funding opportunity was created on 2017-03-09.
- Applicants must submit their applications by 2017-12-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Blueprint Neurotherapeutics Network (BPN) U44 (PAR 17-201) FAQ
What is the Blueprint Neurotherapeutics Network (BPN) U44 opportunity?
The BPN U44 opportunity is a National Institutes of Health (NIH) cooperative agreement designed to help small businesses advance promising small molecule drug programs for nervous system disorders. It emphasizes moving viable candidates into clinical testing, with a milestone-driven plan aimed at progressing toward an Investigational New Drug (IND) submission and first-in-human studies.
What kind of work is this program designed to support?
This program is oriented toward translational drug development rather than early exploratory research. Applicants are expected to propose projects with a reasonable path to a drug candidate and to execute practical, development-focused activities that move compounds closer to IND submission and clinical entry.
What diseases or therapeutic areas are in scope?
The opportunity focuses on small molecule programs for nervous system disorders. The information provided does not list specific indications, but it frames the scope broadly around nervous system therapeutics.
Who is eligible to apply?
The opportunity is specifically aimed at small businesses as eligible applicants.
Are foreign institutions eligible to apply?
No. Foreign institutions are not eligible to apply under the stated terms.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are also not eligible to apply under the stated terms.
Are any foreign components allowed at all?
Foreign components may be allowed in some cases as defined by the NIH Grants Policy Statement. Applicants with international collaborations are expected to closely review eligibility and component rules in the full funding opportunity announcement.
What does it mean that this is a U44 cooperative agreement?
As a U44 cooperative agreement, NIH involvement is typically more hands-on than with a standard grant. While the awardee drives scientific strategy and executes specialized work, the program uses coordinated project management, external experts, and milestone-based decision points to keep development progressing.
How is the project work divided between the small business and NIH-supported resources?
The small business awardee remains responsible for disease- and target-specific aspects of the project, such as specialized assays, proprietary disease models, target validation tools, and biology/pharmacology data that rely on the applicant's expertise. At the same time, the awardee can collaborate with NIH-funded consultants and may optionally use NIH contract research organizations (CROs) for broader drug development capabilities.
Does the grant cover work performed in the awardee's own labs?
Yes. The grant covers work performed in the awardee's own labs for project-specific activities that are part of the disease- and target-specific responsibilities described in the opportunity information.
What kinds of capabilities can NIH contract research organizations (CROs) provide?
NIH CROs can provide capabilities that many small companies do not have in-house, including medicinal chemistry support, pharmacokinetics and ADME studies, safety and toxicology testing, formulation development, scale-up and chemical synthesis, Good Manufacturing Practices (GMP) manufacturing, and Phase I clinical testing.
Is use of NIH CROs required?
The information provided describes the CRO support as optional ("optional use of NIH contract research organizations").
What are the entry points for projects into the program?
Projects can enter at two points depending on maturity: the Discovery stage or the Development stage.
What is expected at the Discovery stage?
Discovery-stage projects aim to take promising "hit" compounds and optimize them through medicinal chemistry and iterative testing. Typical focus areas include potency, selectivity, physicochemical properties, metabolic stability, brain penetration (when relevant), and early safety liabilities. If milestones are met, projects can transition into Development activities under the same overall program pathway.
What is expected at the Development stage?
Development-stage projects are expected to already have a credible development candidate (or be close) and to complete IND-enabling work. This generally includes formal toxicology studies performed under appropriate standards, required pharmacology packages, formulation and manufacturing plans suitable for human dosing, and execution of Phase I clinical testing to evaluate initial safety, tolerability, and pharmacokinetics in humans.
Does the program support movement from Discovery to Development?
Yes. The program is described as allowing Discovery-stage projects that meet agreed milestones to transition forward into Development activities within the same overall program pathway.
What is the overall goal or endpoint emphasized by the program?
The program places a clear emphasis on advancing viable candidates into clinical testing, with activities aligned to IND submission and first-in-human studies. The throughline is practical readiness for clinical entry rather than open-ended research.
How are decisions made about whether a project continues?
The cooperative agreement structure is described as milestone-based, with coordinated project management and decision points intended to prioritize resources toward candidates that continue to meet performance and safety criteria.
What role do consultants and external experts play?
The program is built around collaboration with NIH-funded consultants and the use of external experts as part of coordinated project management, helping provide development infrastructure and discipline.
How does the program address common bottlenecks for small companies?
By pairing the awardee's specialized, disease- and target-specific expertise with access to NIH-supported consultants and optional CRO infrastructure, the program aims to reduce bottlenecks that commonly stall small molecule programs as they transition from discovery into regulated preclinical and clinical workflows.
What is the intellectual property (IP) arrangement for awardees?
Awardee institutions retain their own IP rights and also receive assignment of IP rights from BPN contractors for drug candidates developed within the program. This positions the small business to control downstream patent prosecution and licensing negotiations for candidates advanced through contractor-supported work.
Why is the contractor IP assignment significant?
Because key development steps may be executed by NIH-associated contractors, assignment of contractor IP to the awardee helps ensure participating companies can maintain control of their assets, which can be important for later partnering or investment discussions.
What is the funding opportunity identifier and mechanism?
The funding opportunity is identified as PAR 17-201 and uses the U44 cooperative agreement mechanism.
Which agency offers this opportunity?
The opportunity is offered by the National Institutes of Health (NIH).
How is the funding categorized in the provided information?
It is categorized as discretionary funding.
What CFDA numbers are associated with this opportunity?
The listing aligns with multiple CFDA numbers: 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.865, 93.866, 93.867.
What does it mean that multiple CFDA numbers are listed?
The provided information indicates the multiple CFDA numbers reflect the multi-institute nature of NIH neuroscience and translational therapeutic development efforts.
What was the original closing date shown for this listing?
The original closing date shown is 2017-12-21.
What does the closing date suggest about this specific listing?
The closing date and the record creation date indicate this specific listing refers to a historical solicitation cycle rather than necessarily an active, current deadline.
What is the record creation date shown?
The record creation date shown is 2017-03-09.
What broad activity category is listed for this opportunity?
The activity category is listed broadly under education, health, income security, and social services.
Browse more opportunities from the same category: Education, Health, Income Security and Social Services
Next opportunity: Research and Development
Previous opportunity: Evaluating Natural Experiments in Healthcare to Improve Diabetes Prevention and Treatment (R18)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 17 201
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 17 201) also looked into and applied for these:
| Funding Opportunity |
|---|
| BRAIN Initiative: New Concepts and Early - Stage Research for Large - Scale Recording and Modulation in the Nervous System (R21) Apply for RFA EY 17 002 Funding Number: RFA EY 17 002 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $200,000 |
| BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01) Apply for RFA MH 18 500 Funding Number: RFA MH 18 500 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
| BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01) Apply for RFA MH 18 505 Funding Number: RFA MH 18 505 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24) Apply for RFA NS 18 005 Funding Number: RFA NS 18 005 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Tools to target, identify and characterize non-neuronal cells in the brain (R01 Clinical Trial Not Allowed) Apply for RFA DA 18 018 Funding Number: RFA DA 18 018 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Opioid Use Disorder in Pregnancy (R01) Apply for RFA HD 18 036 Funding Number: RFA HD 18 036 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $500,000 |
| BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 - Clinical Trial Not Allowed) Apply for RFA NS 18 009 Funding Number: RFA NS 18 009 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trials Not Allowed) Apply for RFA EB 17 003 Funding Number: RFA EB 17 003 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $300,000 |
| BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01) (Clinical Trials Not Allowed) Apply for RFA EB 17 004 Funding Number: RFA EB 17 004 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) Apply for RFA EB 17 005 Funding Number: RFA EB 17 005 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) Apply for PA 18 001 Funding Number: PA 18 001 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| The Health of Sexual and Gender Minority (SGM) Populations (R01 Clinical Trial Optional) Apply for PA 18 037 Funding Number: PA 18 037 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| The Health of Sexual and Gender Minority (SGM) Populations (R21 Clinical Trial Optional) Apply for PA 18 040 Funding Number: PA 18 040 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $200,000 |
| The Health of Sexual and Gender Minority (SGM) Populations (R03 Clinical Trial Optional) Apply for PA 18 054 Funding Number: PA 18 054 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $50,000 |
| The Health of Sexual and Gender Minority (SGM) Populations (R15 Clinical Trial Optional) Apply for PA 18 210 Funding Number: PA 18 210 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional) Apply for PA 18 137 Funding Number: PA 18 137 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional) Apply for PA 18 155 Funding Number: PA 18 155 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $200,000 |
| BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) Apply for RFA MH 18 510 Funding Number: RFA MH 18 510 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) Apply for PA 18 286 Funding Number: PA 18 286 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $200,000 |
| Research To Address Sleep Disorders in the Context of Medical Rehabilitation (R01 Clinical Trial Optional) Apply for PAR 18 212 Funding Number: PAR 18 212 Agency: National Institutes of Health Category: Education, Health, Income Security and Social Services Funding Amount: $499,999 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 17 201", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.